Bottom-up modeling and simulation of tacrolimus clearance: Prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power

Hisakazu Ohtani, Zoe Barter, Tsuyoshi Minematsu, Masatoshi Makuuchi, Yasufumi Sawada, Amin Rostami-Hodjegan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The objectives were to investigate the ability of population-based in vitro-in vivo extrapolation (IVIVE) to reproduce the influence of haematocrit on the clearance of tacrolimus, observed previously, and to assess the power of clinical studies to detect the effects of covariates on the clearance of tacrolimus. A population-based pharmacokinetic simulator (Simcyp) was used to simulate tacrolimus clearance from in vitro metabolism data and demographic characteristics of Japanese liver transplant patients (JLTs). The relationship between haematocrit and dose-to-concentration (D/C) ratio was validated using seven JLTs, whose highly variable haematocrit and D/C ratio were previously analysed. This validation was used as a surrogate for establishing 'interindividual' variability and to assess the power of clinical studies to discern the effect of haematocrit, sex and CYP3A5 genotype on tacrolimus clearance in a virtual JLT population. The relationship between haematocrit and D/C ratio was reproducible by Simcyp and corresponded well to those observed in seven JLTs. The number of JLTs required to detect the influence of CYP3A5 genotype and sex were estimated to be about 50 and > 600, respectively, which was consistent with the results of previous population pharmacokinetic studies for tacrolimus. In conclusion, population-based IVIVE is considered to be a useful approach to assess the influence of covariates a priori before conducting clinical studies. This is also helpful with study design and assessment of the statistical power of clinical studies involving population-based pharmacokinetics to detect the effects of covariates.

Original languageEnglish
Pages (from-to)498-506
Number of pages9
JournalBiopharmaceutics and Drug Disposition
Volume32
Issue number9
DOIs
Publication statusPublished - 2011 Dec

Fingerprint

Cytochrome P-450 CYP3A
Sex Distribution
Tacrolimus
Blood Cells
Hematocrit
Population
Pharmacokinetics
Genotype
Demography
Transplants
Clinical Studies
Liver
In Vitro Techniques

Keywords

  • covariate analysis
  • haematocrit
  • in vitro in vivo extrapolation (IVIVE)
  • modeling and simulation
  • population pharmacometrics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmaceutical Science
  • Pharmacology

Cite this

Bottom-up modeling and simulation of tacrolimus clearance : Prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. / Ohtani, Hisakazu; Barter, Zoe; Minematsu, Tsuyoshi; Makuuchi, Masatoshi; Sawada, Yasufumi; Rostami-Hodjegan, Amin.

In: Biopharmaceutics and Drug Disposition, Vol. 32, No. 9, 12.2011, p. 498-506.

Research output: Contribution to journalArticle

@article{37647e42ed75430aa0af618d5975f1bb,
title = "Bottom-up modeling and simulation of tacrolimus clearance: Prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power",
abstract = "The objectives were to investigate the ability of population-based in vitro-in vivo extrapolation (IVIVE) to reproduce the influence of haematocrit on the clearance of tacrolimus, observed previously, and to assess the power of clinical studies to detect the effects of covariates on the clearance of tacrolimus. A population-based pharmacokinetic simulator (Simcyp) was used to simulate tacrolimus clearance from in vitro metabolism data and demographic characteristics of Japanese liver transplant patients (JLTs). The relationship between haematocrit and dose-to-concentration (D/C) ratio was validated using seven JLTs, whose highly variable haematocrit and D/C ratio were previously analysed. This validation was used as a surrogate for establishing 'interindividual' variability and to assess the power of clinical studies to discern the effect of haematocrit, sex and CYP3A5 genotype on tacrolimus clearance in a virtual JLT population. The relationship between haematocrit and D/C ratio was reproducible by Simcyp and corresponded well to those observed in seven JLTs. The number of JLTs required to detect the influence of CYP3A5 genotype and sex were estimated to be about 50 and > 600, respectively, which was consistent with the results of previous population pharmacokinetic studies for tacrolimus. In conclusion, population-based IVIVE is considered to be a useful approach to assess the influence of covariates a priori before conducting clinical studies. This is also helpful with study design and assessment of the statistical power of clinical studies involving population-based pharmacokinetics to detect the effects of covariates.",
keywords = "covariate analysis, haematocrit, in vitro in vivo extrapolation (IVIVE), modeling and simulation, population pharmacometrics",
author = "Hisakazu Ohtani and Zoe Barter and Tsuyoshi Minematsu and Masatoshi Makuuchi and Yasufumi Sawada and Amin Rostami-Hodjegan",
year = "2011",
month = "12",
doi = "10.1002/bdd.777",
language = "English",
volume = "32",
pages = "498--506",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Bottom-up modeling and simulation of tacrolimus clearance

T2 - Prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power

AU - Ohtani, Hisakazu

AU - Barter, Zoe

AU - Minematsu, Tsuyoshi

AU - Makuuchi, Masatoshi

AU - Sawada, Yasufumi

AU - Rostami-Hodjegan, Amin

PY - 2011/12

Y1 - 2011/12

N2 - The objectives were to investigate the ability of population-based in vitro-in vivo extrapolation (IVIVE) to reproduce the influence of haematocrit on the clearance of tacrolimus, observed previously, and to assess the power of clinical studies to detect the effects of covariates on the clearance of tacrolimus. A population-based pharmacokinetic simulator (Simcyp) was used to simulate tacrolimus clearance from in vitro metabolism data and demographic characteristics of Japanese liver transplant patients (JLTs). The relationship between haematocrit and dose-to-concentration (D/C) ratio was validated using seven JLTs, whose highly variable haematocrit and D/C ratio were previously analysed. This validation was used as a surrogate for establishing 'interindividual' variability and to assess the power of clinical studies to discern the effect of haematocrit, sex and CYP3A5 genotype on tacrolimus clearance in a virtual JLT population. The relationship between haematocrit and D/C ratio was reproducible by Simcyp and corresponded well to those observed in seven JLTs. The number of JLTs required to detect the influence of CYP3A5 genotype and sex were estimated to be about 50 and > 600, respectively, which was consistent with the results of previous population pharmacokinetic studies for tacrolimus. In conclusion, population-based IVIVE is considered to be a useful approach to assess the influence of covariates a priori before conducting clinical studies. This is also helpful with study design and assessment of the statistical power of clinical studies involving population-based pharmacokinetics to detect the effects of covariates.

AB - The objectives were to investigate the ability of population-based in vitro-in vivo extrapolation (IVIVE) to reproduce the influence of haematocrit on the clearance of tacrolimus, observed previously, and to assess the power of clinical studies to detect the effects of covariates on the clearance of tacrolimus. A population-based pharmacokinetic simulator (Simcyp) was used to simulate tacrolimus clearance from in vitro metabolism data and demographic characteristics of Japanese liver transplant patients (JLTs). The relationship between haematocrit and dose-to-concentration (D/C) ratio was validated using seven JLTs, whose highly variable haematocrit and D/C ratio were previously analysed. This validation was used as a surrogate for establishing 'interindividual' variability and to assess the power of clinical studies to discern the effect of haematocrit, sex and CYP3A5 genotype on tacrolimus clearance in a virtual JLT population. The relationship between haematocrit and D/C ratio was reproducible by Simcyp and corresponded well to those observed in seven JLTs. The number of JLTs required to detect the influence of CYP3A5 genotype and sex were estimated to be about 50 and > 600, respectively, which was consistent with the results of previous population pharmacokinetic studies for tacrolimus. In conclusion, population-based IVIVE is considered to be a useful approach to assess the influence of covariates a priori before conducting clinical studies. This is also helpful with study design and assessment of the statistical power of clinical studies involving population-based pharmacokinetics to detect the effects of covariates.

KW - covariate analysis

KW - haematocrit

KW - in vitro in vivo extrapolation (IVIVE)

KW - modeling and simulation

KW - population pharmacometrics

UR - http://www.scopus.com/inward/record.url?scp=82155166249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82155166249&partnerID=8YFLogxK

U2 - 10.1002/bdd.777

DO - 10.1002/bdd.777

M3 - Article

C2 - 22028295

AN - SCOPUS:82155166249

VL - 32

SP - 498

EP - 506

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 9

ER -